NCT04257448 - Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 25, 2020

Primary Completion Date

July 2, 2024

Study Completion Date

July 2, 2024

Conditions

Pancreas CancerPancreatic AdenocarcinomaPancreatic Ductal Adenocarcinoma

Interventions

DRUG

Romidepsin

Powder and solvent for solution for infusion; Intravenous use

DRUG

Azacitidine

Powder for suspension for injection; Subcutaneous use

DRUG

nab-Paclitaxel

Powder for suspension for injection; Intravenous use

DRUG

Gemcitabine

Powder for solution for infusion; Intravenous use

DRUG

Durvalumab

Concentrate for solution for infusion; Intravenous use

DRUG

Lenalidomide capsule

Hard capsule for oral use

Trial Locations (9)

20251

Universitätsklinikum Hamburg-Eppendorf, Hamburg

37075

Universitätsmedizin Göttingen, Göttingen

45147

Universitätsklinikum Essen, Essen

50937

Uniklinik Köln, Cologne

60590

Universitätsklinikum Frankfurt, Frankfurt

81377

Ludwig-Maximilians-Universität München, München

89081

Universitätsklinikum Ulm, Ulm

90419

Klinikum Nürnberg, Nuremberg

97080

Universitätsklinikum Würzburg, Würzburg